Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 25;65(16):10848-10881.
doi: 10.1021/acs.jmedchem.2c00867. Epub 2022 Aug 4.

Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives

Rosanna Maccari  1 , Rosaria Ottanà  1
Affiliations
Review

Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives

Rosanna Maccari et al. J Med Chem. .

Abstract

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors (gliflozins) represent the most recently approved class of oral antidiabetic drugs. SGLT-2 overexpression in diabetic patients contributes significantly to hyperglycemia and related complications. Therefore, SGLT-2 became a highly interesting therapeutic target, culminating in the approval for clinical use of dapagliflozin and analogues in the past decade. Gliflozins improve glycemic control through a novel insulin-independent mechanism of action and, moreover, exhibit significant cardiorenal protective effects in both diabetic and nondiabetic subjects. Therefore, gliflozins have received increasing attention, prompting extensive structure-activity relationship studies and optimization approaches. The discovery that intestinal SGLT-1 inhibition can provide a novel opportunity to control hyperglycemia, through a multifactorial mechanism, recently encouraged the design of low adsorbable inhibitors selectively directed to the intestinal SGLT-1 subtype as well as of dual SGLT-1/SGLT-2 inhibitors, representing a compelling strategy to identify new antidiabetic drug candidates.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Structures of phlorizin and selected 4-dehydroxyphlorizin derivatives.
Figure 2
Figure 2
Structures and development of sergliflozin and remogliflozin.
Figure 3
Figure 3
Development of meta-diarylmethane C-glucoside hSGLT-2 inhibitors.
Figure 4
Figure 4
- Dapagliflozin analogues obtained by modifying the distal aryl moiety.
Figure 5
Figure 5
Dapagliflozin- and canagliflozin-derived aryl/heteroaryl C-glucosides.
Figure 6
Figure 6
Development of ipragliflozin.
Figure 7
Figure 7
Structures of selected 3-[(azulen-2-yl)methyl]phenyl C-glucosides.
Figure 8
Figure 8
General structures of macrocyclic C-glycoside derivatives.
Figure 9
Figure 9
Design and SARs of tofogliflozin and derivatives.
Figure 10
Figure 10
Design of luseogliflozin.
Figure 11
Figure 11
SARs of ertugliflozin-derived SGLT-2 inhibitors.
Figure 12
Figure 12
Examples of sugar-modified dapagliflozin derivatives.
Figure 13
Figure 13
Structures of representative xylose-derived SGLT inhibitors.
Figure 14
Figure 14
Development of dual SGLT-1/SGLT-2 inhibitors.
Figure 15
Figure 15
4-Benzyl-1H-pyrazol-3-yl β-d-glycopyranosides endowed with selective hSGLT-1 inhibitory activity.
Figure 16
Figure 16
Sotagliflozin-derived low adsorbable dual SGLT-1/SGLT-2 inhibitors.
Figure 17
Figure 17
Design of new low adsorbable dual SGLT-1/SGLT-2 inhibitors.
Figure 18
Figure 18
Structures of selected aniline-N-glucosides and heteroaromatic-N-glucosides.
Figure 19
Figure 19
Structures of selected 3-benzylindolyl-N-glucosides.
Figure 20
Figure 20
Structures of selected N-linked β-d-xylosides.
Figure 21
Figure 21
Structures of selected C-indolylxylosides.
Figure 22
Figure 22
Selected 3-(4-cyclopropylbenzyl)-1H-indole N-glucosides.
Figure 23
Figure 23
Selected 4-chloro-3-(4-cyclopropylbenzyl)-1H-indole N-glycosides modified at the C-6 position of the sugar moiety.
See this image and copyright information in PMC

References

    1. Sun H.; Saeedi P.; Karuranga S.; Pinkepank M.; Ogurtsova K.; Duncan B. B.; Stein C.; Basit A.; Chan J. C. N.; Mbanya J. C.; Pavkov M. E.; Ramachandaran A.; Wild S. H.; James S.; Herman W. H.; Zhang P.; Bommer C.; Kuo S.; Boyko E. J.; Magliano D. J. IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045. Diabetes Res. Clin. Pract. 2022, 183, 109119. 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
    1. Viner R.; White B.; Christie D. Type 2 Diabetes in Adolescents: A Severe Phenotype Posing Major Clinical Challenges and Public Health Burden. Lancet 2017, 389, 2252–2260. 10.1016/S0140-6736(17)31371-5. - DOI - PubMed
    1. Wilding J. P. H. The Role of the Kidneys in Glucose Homeostasis in Type 2 Diabetes: Clinical Implications and Therapeutic Significance through Sodium Glucose Co-Transporter 2 Inhibitors. Metab. Clin. Exp. 2014, 63, 1228–1237. 10.1016/j.metabol.2014.06.018. - DOI - PubMed
    1. Rahmoune H.; Thompson P. W.; Ward J. M.; Smith C. D.; Hong G.; Brown J. Glucose Transporters in Human Renal Proximal Tubular Cells Isolated from The Urine of Patients with Non-Insulin-Dependent Diabetes. Diabetes 2005, 54, 3427–3434. 10.2337/diabetes.54.12.3427. - DOI - PubMed
    1. Halimi S.; Vergès B. Adverse Effects and Safety of SGLT-2 Inhibitors. Diabetes Metab. 2014, 40, S28–S34. 10.1016/S1262-3636(14)72693-X. - DOI - PubMed

MeSH terms